StemBioSys CEO: Company has room to grow in San Antonio

Bob Hutchens is CEO of StemBioSys Inc. CARLOS JAVIER SANCHEZ | SABJ By W. Scott Bailey – Senior ...

SA researchers exploring use of re-purposed cancer drugs to combat deadly TB

Texas Biomedical Research Institute President and CEO Dr. Larry Schlesinger, right, with Eusondia Arnett, ...

DPT Laboratories appoints executive to lead R&D
February 22, 2012

By James Aldridge, San Antonio Business Journal

DPT Laboratories has named Kuljit Bhatia the company's new vice president of research and development at the contract development and manufacturing organization.

Bhatia, who has more than 15 years of pharmaceutical experience in drug product development, previously was vice president of research and development and technical operations at Fougera Pharmaceuticals in Long Island, N.Y.

At DPT, Bhatia will lead the research and pharmaceutical development group and oversee DPT's Center of Excellence for Research & Development in San Antonio. R&D activities include pre-formulation and formulation development strategies for the manufacture of topical and liquid pharmaceutical products, analytical development and validation, process optimization and transfer to manufacturing centers.

"Dr. Bhatia brings extensive experience in comprehensive pharmaceutical development services, along with specific expertise in the area of topical pharmaceutical products, which applies directly to the semi-solid and liquid dosage forms that are our focus at DPT," said Paul Johnson, president of DPT. "His broad understanding of the development process will be a critical asset in our efforts to enhance our continuum of services."

DPT Laboratories is based in San Antonio.


Stay informed. Subscribe to BioMed SA news alerts.